A Phase 3, Multicenter ,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
A Phase 3, Multicenter ,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
This is a clinical study evaluating the efficacy and safety of rivipansel (GMI-1070) in treating subjects with sickle cell disease (SCD) who are 6 years of age or older experiencing a pain crisis necessitating hospitalization.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20001, United States
Atlanta, Georgia 30303, United States
Atlanta, Georgia 30322, United States
Atlanta, Georgia 30342, United States
Louisville, Kentucky 40202, United States
Baltimore, Maryland 21201, United States
Boston, Massachusetts 02115, United States
Jackson, Mississippi 39216, United States
New Brunswick, New Jersey 08901, United States
Brooklyn, New York 11203, United States
Brooklyn, New York 11203, United States
Cincinnati, Ohio 45219, United States
Columbus, Ohio 43210, United States
Charleston, South Carolina 29425, United States
Richmond, Virginia 23298, United States